



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

15 March 2023  
EMA/124155/20233  
Human Medicines Division

## Overview of (invented) names reviewed in February 2023 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 27-30 March 2023

	NRG meeting 14-15 Feb 2023		NRG meeting 26 Apr 2023		NRG meeting 26-27 Jun 2023		NRG meeting 18-19 Sep 2023		NRG meeting 14-15 Nov 2023		2023 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names*	52	51									52	51
Justification for retention of (invented) name **	0	7									0	7

\*Includes invented names, INN+MAH/TM and re-use applications.

\*\*In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.

---

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands  
**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)  
**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



	NRG meeting 14-15 Feb 2023		NRG meeting 26 Apr 2023		NRG meeting 26-27 Jun 2023		NRG meeting 18-19 Sep 2023		NRG meeting 14-15 Nov 2023		2023 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Total number of objections raised	88	155									<b>88</b>	<b>155</b>
Similarity with other (invented) name	53	173									<b>53</b>	<b>173</b>
Conveys misleading therapeutic/pharmaceutical connotations	5	0									<b>5</b>	<b>0</b>
Misleading with respect to composition	0	0									<b>0</b>	<b>0</b>
Similarity with INN	8	17									<b>8</b>	<b>17</b>
Inclusion of INN stem	3	0									<b>3</b>	<b>0</b>
Unacceptable qualifiers	0	0									<b>0</b>	<b>0</b>
Conveys a promotional message	4	7									<b>4</b>	<b>7</b>
Appears offensive or has an inappropriate connotation	5	1									<b>5</b>	<b>1</b>
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0									<b>0</b>	<b>0</b>
Similarity between name of prodrug and related active substance	0	0									<b>0</b>	<b>0</b>
Others	10	2									<b>10</b>	<b>2</b>

See Guideline on the [Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure \(EMA/CHMP/287710/2014\)](#) for detailed explanations of criteria used.